Sugemalimab - CAS 2256084-03-2

Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma.

PD-1/PD-L1

Apoptosis, Immunology/Inflammation, Cell Cycle/Checkpoint

2256084-03-2

0.95

-20°C

Ice Packs

Inhibitory Antibodies